2020 edition coming soon! Stay tuned!

Presenting Companies

Alnylam Pharmaceuticals

Headquartered in Cambridge/MA, Alnylam is leading the translation of RNA interference (RNAi) into a new class of innovative medicines. Based on Nobel Prize-winning science, RNAi therapeutics represent a clinically validated approach for the treatment of diseases with high unmet need. Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality, and is now advancing a robust pipeline of investigational RNAi therapeutic medicines, including four investigational medicines in late-stage development and one product commercialized in the US, European Union, Japan and Canada, with plans to expand to markets around the world. For more information visit www.alnylam.com.